Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...

Moderna launched its RSV vaccine last year ... miss on interim CMV efficacy. All represent headwinds to growth prospects in 2025 — with CMV the largest single line-item at risk among the ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to ... and will evaluate the efficacy, safety, and immunogenicity of mRNA-1403 across two seasons.

The stellar efficacy and safety profile of Moderna's covid vaccine offered rapid validation of the firm's mRNA technology. Its mRNA technology could allow the firm to compete in a wide range of ...

Moderna has also filed for approval for a combination Covid-flu shot. And the company anticipates efficacy data this year from late-stage studies of vaccines for seasonal flu and norovirus ...

Robert F. Kennedy Jr., the HHS secretary nominee, has said he is not antivaccine, but he has a track record of casting doubt ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.